Symbols

KYTX

Kyverna·NASDAQ

--(--)

KYTX Profile

Kyverna Therapeutics, Inc.

A clinical-stage biopharmaceutical company developing solutions for autoimmune diseases

Industry

Biological Technology

Established Date

06/14/2018

Listing Date

02/08/2024

Exchange

NASDAQ Stock Exchange

Full-time Employees

130

Fiscal Year Ends

12-31

Website

kyvernatx.com

Security Type

Common stock

Office address

5980 Horton St. STE 550 Emeryville CA 94608

Business

Introduction

Kyverna Therapeutics, Inc., was incorporated in Delaware on June 14, 2018 under the name BAIT Therapeutics, Inc., and changed its name to Kyverna Therapeutics, Inc., in October 2019. The company is a patient-centric clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The company's goal is to bring disease-modifying therapeutic benefits to patients with autoimmune diseases through a patient-centered approach, a broad platform, insights into the treatment of immune diseases, and lessons learned from the successful application of cell therapy in the medical field.